This site is intended for healthcare professionals

Positive topline results from phase III trial of tislelizumab + chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer. - BeiGene

Read time: 1 mins
Last updated:24th May 2021
Published:22nd May 2021
BeiGene, Ltd. announced that the Phase III RATIONALE 309 trial of its anti-PD-1 antibody tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC) met its primary endpoint of progression-free survival (PFS) at the interim analysis, as recommended by an independent data monitoring committee.
Condition: Nasopharyngeal Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest